Inhibitors of SP140 and their use in therapy

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time for Utility, Provisional or Design Patent Creation with PowerPatent software and services.

The Glaxo Group Limited patent solves the following problem:

Chromatin is the complex combination of DNA and proteins that makes up chromosomes. It is found in the nuclei of eukaryotic cells and divided between heterochromatin (condensed) and euchromatin (height) forms. A range of different states of pressure and tension can structure varies during the cell cycle, the most compact during the process of cell division. The major components of chromatin DNA and proteins. Histones are the chief protein components of chromatin, act as spools around which DNA winds. The basic building blocks of chromatin nucleosomes, each of which is composed of 146 base pairs of DNA wrapped around a histone octamer consisting of 2 copies of each H2A, H2B, H3 and H4. The functions of chromatin is to package DNA into a smaller volume to fit in the cell, to strengthen the DNA to allow mitosis and meiosis, and to serve as a mechanism to control the expression and DNA copying. Chromatin contains genetic material that serve as instructions to direct the work cell. The genomes of eukaryotic organisms that organized inside the nucleus of cells. The chromatin structure controlled by a series of post translation modifications of histone proteins, mainly histones H3 and H4, and most often in the histone tails that extend beyond the core nucleosome structure. Histone tails tend to be free for proteinprotein interaction and also on the part of the histone most prone to post-translation modifications. These changes include acetylation, methylation, phosphorylation, ubiquitinylation, SUMOylation. These epigenetic marks that are written and erased by the specific enzyme, put the tag on specific residues in histone tails, thus building an epigenetic code, which will be expressed in the cell allowing gene specific regulation of chromatin structure and transcription.

Our analysis of this patent is as follows:

Glaxo Group Limited’s patent US 9018184 B2 deals with Inhibitors of SP140 and their use in therapy.
A method of treating autoimmune and inflammatory diseases or conditions in a mammal, such as a man, comprising the administration of an inhibitor of bromodomain-containing protein: SP140.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Power saving receiver circuits, systems and processes

Patent Registration – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Texas Instruments Incorporated patent solves the following problem:

GPS (Global Positioning System) is a ground-satellite-based electronic system for enabling GPS receivers on ships, airplanes, land vehicles and ground stations to determine their geographic and spatial position such as latitude, longitude, and altitude. Discussion on GPS is not limited to other similar electronic systems as well as receiver circuits use a variety of telecommunications systems.

Our analysis of this patent is as follows:

Texas Instruments Incorporated’s patent US 9020459 B2 deals with Power saving receiver circuits, systems and processes.
An electronic circuit includes a receiver circuit (BSP) operable to create coherent collective with a coherent sal the general time period, and a power control circuit (2130) coupled to said receiver circuit (BSP) and operable to impress a power controlling the duty cycle (TON, TOFF) receiver circuit (BSP) for coherent sal compound. Some circuits, devices, systems, methods of operation and the process of making the states.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Method of screening for compounds useful in the treatment of insulin resistance, impaired glucose tolerance or diabetes

Apply for Patent – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Arena Pharmacueticals, Inc. patent solves the following problem:

These cells use glucose as a primary energy source. Therefore, the first food waste in the body to glucose before use. Glucose then released from the gut into the blood resulting in an increase in the level of glucose in the blood. In response to this increase in the levels of glucose, pancreatic -islet cells to increase their production and secretion of insulin. Insulin circulates through the blood and act like an angel, to send a signal to the insulin responsive organs such as adipose tissue, liver and muscles, to increase their food into glucose. In this way a rise in blood glucose accompanied by a subsequent increase in insulin secretion from the -cells. This is increasing the insulin act to return blood glucose levels to normal. In healthy individuals blood glucose levels kept fairly constant. This state of equilibrium, called normoglycemia (normal glucose levels) is strictly controlled by insulin.

Our analysis of this patent is as follows:

Arena Pharmacueticals, Inc.’s patent US 9017949 B2 deals with Method of screening for compounds useful in the treatment of insulin resistance, impaired glucose tolerance or diabetes.
The present invention relates to a method for identifying a metabolic stabilizing compound: a) contacting a candidate compound with GPR43, and b) determining whether GPR43 functionality modulated, wherein a modulation in GPR43 functionality is indicative of the candidate compound being a metabolic stabilizing compound. Furthermore, the invention relates to a method for identifying a metabolic stabilizing compound, comprising: a) contacting a candidate compound with GPR43, and b) determining whether GPR43 equipment functionality is increased, wherein an increase in GPR43 functionality is indicative of the candidate compound being a metabolic stabilizing compound. Furthermore, the invention relates to a method for identifying a metabolic stabilizing compound, comprising: a) contacting a candidate compound with GPR43, and b) determining whether GPR43 equipment , declined purpose, where a decrease in GPR43 functionality is indicative of the candidate compound being a metabolic stabilizing compound.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Anti-FcRH5 antibodies and immunoconjugates and methods of use

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Genenech, Inc. patent solves the following problem:

Malignant tumors (cancers) are the second leading cause of death in the United States, after heart disease (Boring et al, CA Cancel J. Clin 43: 7 (1993)). Cancer is characterized by the increase in the number of abnormal, or neoplastic, cells derived from a normal tissue which proliferate to form a tumor mass, the invasion of adjacent tissues by these neoplastic tumor cells, and the generation of malignant cells which eventually spread through the blood or lymphatic system to regional lymph nodes and distant sites via a process called metastasis. In a cancerous state, a cell proliferates under conditions in which normal cells would not grow. Cancer manifests itself in a wide variety of forms, characterized by different degrees of invasiveness and aggressiveness.

Our analysis of this patent is as follows:

Genenech, Inc.’s patent US 9017951 B2 deals with Anti-FcRH5 antibodies and immunoconjugates and methods of use.
One way to determine the presence of FcRH5 in a biological sample suspected of containing FcRH5 provided comprising exposing biological samples in an isolated monoclonal anti-FcRH5 antibody.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Semiconductor apparatus, manufacturing apparatus, and manufacturing method

Patent Registration – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Sony Corporation patent solves the following problem:

For example, there is a semiconductor apparatus 1 serving as a camera module for a picture of something with the photo-electric conversion of light from the outside, as shown in FIG. 1a. The semiconductor equipment 1 basically formed a printed substrate 21, an imaging chip 22, an infrared cutoff filter 23, and a lens 24.

Our analysis of this patent is as follows:

Sony Corporation’s patent US 9018728 B2 deals with Semiconductor apparatus, manufacturing apparatus, and manufacturing method.
A semiconductor apparatus includes: a first sheet-like member having a light receiving surface of an imaging device and a first connection terminal disposed thereon, the imaging devices to create a image by receiving incident light from a light collecting section for collecting external light disposed thereon; a second sheet-like member having a second connection terminal connected to a first connection terminal provided thereon; a conductive part of a relationship made of a conductive material and a closer connection to the first terminal; and a relationship wire connecting the conductive part of bail and the second connection terminal, which would bail wire along the plane first sheet-like member such that the light appeared from the bonding wire does not impinge the light receiving surface.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Highly effective anti-cadherin antibody for induction of antibody-dependent cellular cytotoxicity in vivo

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with PowerPatent’s Utility, Provisional or Design Patent Filing Software

The The University Of Tokyo, , Perseus Proteomics Inc. patent solves the following problem:

Cancer is a very important disease to be a leading cause of death, but the therapeutic needs not yet satisfied. In recent years, to solve the problem with the conventional chemotherapy affect normal cells, a cancer treatment using a molecular-targeted agents, which will be studied. In cancer treatment, an agent designed to target a specific molecule specifically expressed in cancer cells, and cancer treatment with such agents designed.

Our analysis of this patent is as follows:

The University Of Tokyo, , Perseus Proteomics Inc.’s patent US 9017683 B2 deals with Highly effective anti-cadherin antibody for induction of antibody-dependent cellular cytotoxicity in vivo.
It is a thing of the present invention to provide an anti-Cadherin antibody with high antibody-dependent cellular cytotoxicity. The present invention provides an anti-Cadherin antibody, which belonged to any one of a surface region EC1, a Cadherin domain 4 (EC4) and a Cadherin domain 5 (EC5), which an antibody-dependent cellular cytotoxicity of an antibody concentration of 1 g / ml was 30% or more.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Multispecific antibodies

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Genentech, Inc. patent solves the following problem:

Antibody specific immunoglobulin polypeptides produced by the vertebrate immune system in response to the challenge of foreign proteins, glycoproteins, cells, or other antigenic foreign substances. An important part of this process is the generation of antibodies that bind specifically to a particular foreign substance. The binding specificity of such polypeptides to a particular antigen is very refined, and the multitude of specificities capable of being generated by the individual vertebrate unique in its complexity and variability. Thousands of antigens are capable of eliciting responses, each almost exclusively directed to the particular antigen which elicited it.

Our analysis of this patent is as follows:

Genentech, Inc.’s patent US 9017686 B2 deals with Multispecific antibodies.
invention provides multispecific antibodies and methods of making and using such antibodies.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Pathway for Th-17 cell development and methods utilizing same

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with a PowerPatent Utility, Provisional or Design Patent Application

The The Uab Research Foundation patent solves the following problem:

The Th1 / Th2 paradigm provides the framework for understanding the CD4 + T-cell Biology and the interplay between innate and adaptive immunity in nearly two decades. The adaptive immune response is essential for the eradication of infectious agents, although dysregulated adaptive immune responses can also lead to autoimmune and chronic inflammatory diseases. A major part of the adaptive immune response is the CD4 + T cells, which orchestrate the functional activity of the innate and adaptive immune systems. Directed division of effector CD4 + T cells to cytokines produced by the pathogen-activated cells of the innate immune system provides a mechanism to coordinate the innate and adaptive immune responses to the greatest protection the flock. Classically, effector CD4 + T cells that are divided into two separate lineages on the basis of their cytokine production profile: T helper cells (th) 1 seed, have evolved to improve the elimination of intracellular pathogens (eg intracellular bacteria, viruses and some protozoa), the nature of their production of interferon gamma (IFN-), a potent activator of cell-mediated immunity; and Th2 cells species, have evolved to promote the elimination of parasitic infection (eg helminths), the nature of the production of interleukin (IL) -4, IL-5 and IL-13, which are potent activators B-cell immunoglobulin (Ig) E production, eosinophil recruitment and mucosal expulsion mechanism (mucous production and hypermotility). Immune pathogenesis resulting from dysregulated Th1 response to themselves or commensal flower antigens may increase tissue destruction and chronic inflammation, while dysregulated Th2 responses can cause allergies and asthma.

Our analysis of this patent is as follows:

The Uab Research Foundation’s patent US 9017685 B1 deals with Pathway for Th-17 cell development and methods utilizing same.
The present disclosure showed for the first time Th-17 cells are the product of a different CD4 + T cell generation to the unique developmental and functional characteristics. The developmental signals required for Th-17 commitment and development are also described. As a result, the teachings of the present disclosure provide a basis for understanding the developmental path of Th-17 cells and offer novel ways again (stimulate or inhibit) this developmental program and offer new methods for the treatment and prevention of disease states and conditions related to aberrant activity of Th-17 cells.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Chromatography matrices including novel Staphylococcus aureus protein a based ligands

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with a PowerPatent Utility, Provisional or Design Patent Application

The Emd Millipore Corporation patent solves the following problem:

Ligands used in affinity chromatography often yield a high selectivity for the target molecule, thus resulting in high yield, high purity and fast economic and purification of target molecules. Staphylococcus aureus Protein A-based reagents and chromatography matrices found a widespread use in the field of affinity chromatography for capture and purification of antibody and Fc-containing proteins as well as the analytical-scale method of antibody detection because of its ability to bind IgG, without significantly affecting the affinity immunoglobulin antigen.

Our analysis of this patent is as follows:

Emd Millipore Corporation’s patent US 9018305 B2 deals with Chromatography matrices including novel Staphylococcus aureus protein a based ligands.
The present invention relates to chromatography matrices including ligands based on one or more domains of immunoglobulin-binding protein such as Staphylococcus aureus Protein A (SpA), as well as methods of using the same .

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Modulating PDX-1 with PCIF1, methods and uses thereof

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with PowerPatent’s Utility, Provisional or Design Patent Filing Software

The The Trustees Of The University Of Pennsylvania patent solves the following problem:

Diabetes results from an imbalance between the production of insulin by the pancreatic -cell and metabolic insulin action in tissues such as the liver, fat and muscle. In type 1 diabetes, an autoimmune attack endogenous cells results in nearly complete insulin deficiency, whereas in type 2 diabetes, resistance to the action of insulin is a major component pathophysiology. Pancreatic cells that have the remarkable ability to compensate for the insulin resistance by increasing insulin synthesis and secretion, and by expanding the number of cells. Therefore, hyperglycemia and the attendant complications of chronic hyperglycemia on kidney, eye, and heart, causing blindness, kidney failure and heart disease, can only result when cells fail to compensate for the genetic or environmental insult prompting. Therefore, the effort to understand the development of the island beta cell mass and improve the island paid for insulin resistance can lead to successful therapeutic strategies for the treatment of all forms of diabetes.

Our analysis of this patent is as follows:

The Trustees Of The University Of Pennsylvania’s patent US 9018163 B2 deals with Modulating PDX-1 with PCIF1, methods and uses thereof.
This invention relates to PCIFl and use it as a target for the development of pancreatic islet cell mass and function in diabetes. In particular, the invention relates to the use of compounds capable of modulating the expression or function of PClFl and their effect on the function of PDX-1.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.